| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 08/18/2005 | CA2554760A1 Use of a complex of ginkgo flavonoids and phosphatidylserine for enhanced cognitive function |
| 08/18/2005 | CA2554620A1 Pyrazoloacrydone derivative-containing solution |
| 08/18/2005 | CA2554262A1 Sustained-release preparations |
| 08/18/2005 | CA2553899A1 Chemically-modified human growth hormone receptor antagonist conjugates |
| 08/18/2005 | CA2553658A1 Microemulsion formulations comprising particular substance p antagonists |
| 08/18/2005 | CA2553040A1 Modified human four helical bundle polypeptides and their uses |
| 08/18/2005 | CA2553039A1 Antiparasitic composition |
| 08/18/2005 | CA2553035A1 Modified human growth hormone polypeptides and their uses |
| 08/18/2005 | CA2553034A1 Modified human interferon polypeptides and their uses |
| 08/18/2005 | CA2552925A1 Semisolid matrix pharmaceutical formulations |
| 08/18/2005 | CA2548210A1 Methods of enhancing immune response in the intradermal compartment and compounds useful in the methods |
| 08/18/2005 | CA2547843A1 Composition comprising polymeric material and uses thereof |
| 08/17/2005 | EP1564236A1 Modified biological substance, process for producing the same, and intermediate |
| 08/17/2005 | EP1564220A1 Sustained release drug carrier |
| 08/17/2005 | EP1564219A1 N-terminally monopegylated polypeptides and process for their preparation |
| 08/17/2005 | EP1563856A1 Thrombin-carrying bioabsorbable synthetic nonwoven fabric |
| 08/17/2005 | EP1563851A1 Antibody linked cationic emulsions as drug delivery system |
| 08/17/2005 | EP1563850A2 Method of increasing the bioavailability and tissue penetration of azithromycin |
| 08/17/2005 | EP1563847A1 Agent eleveting dendritic cell precursor level in blood |
| 08/17/2005 | EP1563844A2 Wound healing formulations containing human plasma fibronectin |
| 08/17/2005 | EP1563834A1 Hollow nanoparticles of protein and drug using the same |
| 08/17/2005 | EP1563832A1 Liposome comprising a compound containing 2 polyalkylene glycol groups |
| 08/17/2005 | EP1562634A1 Positional isomers of peg ifn alpha 2a |
| 08/17/2005 | EP1562633A1 Pharmaceutical product for endonasal administration for treating central nervous system diseases and disorders |
| 08/17/2005 | EP1562630A2 Injectible bioadhesive polymeric hydrogels as well as related methods of enzymatic preparation |
| 08/17/2005 | EP1562627A2 Corticosteroid conjugates and uses thereof |
| 08/17/2005 | EP1562620A2 Modified cytokines for use in cancer therapy |
| 08/17/2005 | EP1562585A1 Daily melatonin dosing units |
| 08/17/2005 | EP1562573A1 Pharmaceutical pellets comprising tamsulosin and a process for making the same |
| 08/17/2005 | EP1562572A2 Pharmaceutical solutions of modafinil compounds |
| 08/17/2005 | EP1562568A1 Treatment of heaves |
| 08/17/2005 | EP1562559A2 Bio-degradable colloid particles, in particular for pulmonary applications |
| 08/17/2005 | EP1562546A1 Depot formulations of arylheterocyclic active agents in the form of a suspension |
| 08/17/2005 | EP1519979A4 Poly-gamma-glutamate having ultra high molecular weight and method for using the same |
| 08/17/2005 | EP1429617A4 Methods for sterilizing preparations of digestive enzymes |
| 08/17/2005 | EP1411895B1 Oral pharmaceutical composition comprising an active principle capable of being subjected to high effect during its first passage through the intestine |
| 08/17/2005 | EP1173178B1 Composition comprising apomorphine and sildenafil and the use thereof for the treatment of erectile dysfunction |
| 08/17/2005 | EP1066004B1 Steam-generating pad |
| 08/17/2005 | EP1051500B1 Diagnosis and treatment of aur1 and/or aur2 related disorders |
| 08/17/2005 | EP0975674B1 Immunotoxins, comprising an onc protein, directed against malignant cells |
| 08/17/2005 | EP0972520B1 Freeze-dried composition of bone morphogenetic protein human mp52 |
| 08/17/2005 | EP0732930B1 Compositions which inhibit apoptosis, methods of purifying the compositions and uses thereof |
| 08/17/2005 | CN1656205A Stabilization of granules |
| 08/17/2005 | CN1656178A Oil-soluble pigment compositions |
| 08/17/2005 | CN1655847A Self-administered contraceptive injection of oily solution |
| 08/17/2005 | CN1655826A Non-viral gene delivery system |
| 08/17/2005 | CN1655825A Non-viral gene delivery system |
| 08/17/2005 | CN1655824A Stabilised pharmaceutical compositions on the basis of polyoxyethylated castor oil and method for manufacturing the same |
| 08/17/2005 | CN1655823A Topically applicable pharmaceutical preparation |
| 08/17/2005 | CN1655812A Anitmicrobial polymer conjugates |
| 08/17/2005 | CN1655805A Chewable compositions containing a gel-forming extract of psyllium |
| 08/17/2005 | CN1655801A Method for the protection of endothelial and epithclial cells during chemotherapy |
| 08/17/2005 | CN1655794A Norethindrone sustained release formulations and methods associated therewith |
| 08/17/2005 | CN1655791A Peritoneal dialysis solution with taurolidine |
| 08/17/2005 | CN1655790A Medicinal composition |
| 08/17/2005 | CN1655789A New pharmaceutical compositions containing flibanserin polymorph A |
| 08/17/2005 | CN1655782A Ophthalmological use of roflumilast for the treatment of diseases of the eye |
| 08/17/2005 | CN1655772A Plaster containing fentanyl |
| 08/17/2005 | CN1655771A At least partially degradable films containing an active ingredient and method for the production thereof |
| 08/17/2005 | CN1655770A Chewable soft capsule |
| 08/17/2005 | CN1655769A Polysaccharide capsules and methods of preparation |
| 08/17/2005 | CN1655768A Oral dosage form for controlled drug release |
| 08/17/2005 | CN1655767A Coated particles with prolonged release and tablets containing same |
| 08/17/2005 | CN1655766A Sustained release of guaifenesin combination drugs |
| 08/17/2005 | CN1655765A Sustained release pharmaceutical preparations and methods for producing the same |
| 08/17/2005 | CN1655764A Compositions and methods for dosing liposomes of certain sizes to treat or prevent disease |
| 08/17/2005 | CN1655763A Method for preparing polymer micelle pharmaceutical preparation containing drug for injection |
| 08/17/2005 | CN1655762A Ibuprofen suspension |
| 08/17/2005 | CN1655761A Modified release pharmaceutical formulation |
| 08/17/2005 | CN1655760A Immediate release pharmaceutical formulation |
| 08/17/2005 | CN1654510A Nano microgel and its preparing process and use |
| 08/17/2005 | CN1654478A Method for preparing polyethylene glycol-modified alpha-interferon 1b |
| 08/17/2005 | CN1214818C Copolymeric micelle drug compsn. and method for the prepn. thereof |
| 08/17/2005 | CN1214792C Highly absorbable solid preparation |
| 08/17/2005 | CN1214789C Delta 9 tetrahydrocannabinol (delta 9 THC) solution metered dose inhalers and methods of use |
| 08/17/2005 | CN1214783C Method for producing controlled releasing drug formulation or its precursor, the drug formulation and the precursor |
| 08/17/2005 | CN1214781C Hybrid matrices and hybrid matrix mixtures |
| 08/16/2005 | US6930119 Liquid pharmaceutical composition |
| 08/16/2005 | US6930090 Methods of activating a receptor using amphiphilic drug-oligomer conjugates |
| 08/16/2005 | US6930087 Pharmaceutical composition comprising factor VIII and neutral liposomes |
| 08/16/2005 | US6930086 Erythropoietin mutein for use in the treatment of anemia |
| 08/16/2005 | US6929955 Interactive system for presenting and eliminating substances |
| 08/16/2005 | US6929950 For implanting/transfecting monodispersed silicon particles joined to DNA into target tissue, cell or the blood stream |
| 08/16/2005 | US6929941 Chimeric cell-targeting pathogenic organism and method of therapeutic use |
| 08/16/2005 | US6929884 For controlled release, by dissolving cellulose in a polar solvent such as dimethylacetamide comprising an alkali metal salt, for example lithium chloride, dispersing the solid in the solution and gelling the solution with water to form a film |
| 08/16/2005 | US6929818 Methods and clinical devices for the inhibition or prevention of mammalian cell growth |
| 08/16/2005 | US6929803 Dosage forms that permit the controlled release of liquid, active agent formulations |
| 08/16/2005 | US6929801 Antiparkinson agent, dermal penetration enhancer of a safe skin-tolerant sunscreen ester and a volatile liquid |
| 08/16/2005 | US6929797 Targeted therapeutic delivery of vitamin D compounds |
| 08/16/2005 | US6929796 Methods to treat undesirable immune responses |
| 08/16/2005 | US6929794 IL-12 as an adjuvant for Bordetella pertussis vaccines |
| 08/16/2005 | US6929793 Nutritional composition for treating an immune condition |
| 08/16/2005 | CA2355293C Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
| 08/16/2005 | CA2337046C Sustained release pharmaceutical preparation |
| 08/16/2005 | CA2280985C Compound containing urea and use of the compound in the field of cosmetics and/or dermatology |
| 08/16/2005 | CA2273094C Gel formulations for topical drug delivery |
| 08/16/2005 | CA2269707C Soluble form osmotic dose delivery system |
| 08/16/2005 | CA2236164C Pulmonary surfactant peptide solubilization process |
| 08/16/2005 | CA2131350C Sustained release drug formulation containing a tramadol salt |
| 08/16/2005 | CA2098533C Carrier system against gnrh |